INTRODUCTION
. However, the experiments in which whole inactiIn spite of the unsuccessful results obtained so far, vated SIV grown in human cells was used for vaccination the elaboration of an effective vaccine is today still the and challenge produced controversial results. Thus, sevonly hope of circumventing the dramatic worldwide eral investigations showed that protection against virus spread of HIV infection. New original strategies have to challenge did not correlate with anti-SIV-specific immube assessed, and for this purpose, investigators have at nity but with the anti-human immunity elicited by cellular their disposal relevant primate models of human HIV antigens which were associated with the virus envelope infection and disease. One of these is experimental infecand had been incorporated into the inactivated vaccine tion of the macaque with primate lentiviruses such as preparation (Arthur et al., 1992; Bergmeier et al., 1994; simian immunodeficiency virus (SIV) or HIV-2 (Desrosiers Cranage et al., 1993; Langlois et al., 1992; Le Grand et et al., 1989; Dormont et al., 1989) . SIV is a retrovirus Mills et al., 1992; Stahl-Hennig et al., 1993 ; Stott, which is indeed closely related to HIVs, both biologically 1991). Hopes were recently turned toward the use of and genetically (Chakrabarti et al., 1987; Guyader et al., live-attenuated viruses as vaccines. Many recent studies 1987); it has the same CD4 molecule as cellular receptor showed that after subsequent experimental superinfecand infects T cells as well as monocyte/macrophages. tion with homologous or heterologous pathogenic viIn addition, SIV induces chronic infection in macaques ruses, intravenous infection with a nonpathogenic attenand some SIV strains generate immunodeficiency uated virus conferred protection or, at least, prevented (Baskin et al., 1988; Daniel et al., 1985; Desrosiers, 1990;  disease progression (Almond et al., 1995; Daniel et al., Letvin et al., 1985; McClure et al., 1989) . Among the large 1992). Putkonen et al. recently reported that infection of number of SIV and HIV-2 vaccine preparations that have macaques with a nonpathogenic strain of HIV-2 had a been tested in nonhuman primates, only the whole inacti-''vaccine effect'' against a subsequent intravenous inocuvated or live-attenuated viruses are able to confer proteclation of the heterologous and highly pathogenic SIVsm tion from infection or, at least, from disease progression strains (Putkonen et al., 1995) . The monkeys in their ex- (Desrosiers et al., 1989; Johnson et al., 1992; periments were not in fact protected from SIV infection, al., 1992 SIV infection, al., , 1990 Murphey-Corb et al., 1989; but the progression of disease was significantly delayed.
To assess the immune efficacy of their strategy against protocol in which rhesus macaques, chronically infected HIV-2 virus isolation from PBMCs with HIV-2 ROD for 2 to 6 years (Nicol-Jourdain et al., After HIV-2 inoculation, the animals were bled regu-1993), were challenged intrarectally with a pathogenic larly. Fresh rhPBMCs were separated by standard denSIVmac251 virus strain obtained from spleen cells of an sity gradient centrifugation (MLS; Eurobio, Les Ulis, infected monkey and propagated in fresh rhesus periphFrance), washed in phosphate-buffered saline (PBS), and eral blood mononuclear cells (rhPBMCs) (Le Grand et cocultured with human cord blood mononuclear cells al., 1992).
(huCBMCs), using 5 1 10 6 rhPBMCs for 10 7 huCBMCs. Human cells were prestimulated for 3 days with 10 mg/ ml phytohemagglutinin-P (Sigma, St. Louis, MO). Cells
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were cultured in RPMI 1640 (Boehringer, Mannheim, Germany) supplemented with 10% heat-inactivated fetal calf Animals serum (Boehringer), 20 mM L-glutamine (Gibco BRL, NY), 1% triantibiotic solution containing penicillin, streptomyEight rhesus monkeys (Macaca mulatta) comprising 1 cin, and neomycin (Gibco BRL), 2 mg/ml polybrene female and 7 males were imported from China and (Sigma), 10 07 IU ml 01 of anti-recombinant interferon-a housed in single cages in level 3 biosafety facilities. All antibodies (Sigma), and 10 IU of human recombinant macaques were negative for SIV and STLV (simian T interleukin-2 (IL-2) (Boehringer). Virus production in sulymphotropic virus) before HIV-2 inoculation. Animals unpernatants was evidenced by detecting reverse tranderwent periodic clinical examination under ketamine scriptase activity as previously described (Barré -Sinoussi chlorhydrate anesthesia (Rhone-Mé rieux, Lyon, France). et al., 1983) . Blood samples were collected weekly for hematologic, virologic, and immunologic analysis for 4 weeks after Detection of circulating infected cells after SIV inoculation with SIV and monthly thereafter. All experichallenge mental procedures were conducted according to the European ''Council Directive on the Protection of Animals
The assay for detection of infected cells after SIV chalUsed for Experimental and other Scientific Purposes'' (86/ lenge was performed using fresh Ficoll-isolated monkey 609/EEC, Journal Officiel des Communauté s Europé enPBMCs. Cocultures were performed using 4 1 10 6 nes, L358; December 18, 1986). CEMX174 human cells for 2 1 10 6 rhPBMCs in the standard culture medium described above but not supplemented with IL-2. Virus production was evidenced by Viruses detection of the p27 antigen using an SIV core Ag assay (Retrovirology Coulter Corporation, Hialeah, FL). For the HIV-2 ROD and EHO isolates were kindly provided by Professor L. Montagnier (Institut Pasteur, Paris, France) titration of cell-associated virus load, threefold dilutions of rhPBMCs were cocultivated in triplicate in 96-well flatand were propagated in vitro only in human peripheral blood mononuclear cells (huPBMCs). Six rhesus mabottomed culture plates (Labware/Falcon, Lincoln Park, NJ) with 12.5 1 10 4 CEMX174 cells, in a total volume of caques were intravenously and intracerebrally inoculated in 1987 with the HIV-2 ROD or EHO isolates. These 200 ml of culture medium . Cultures were maintained in a 5% CO 2 humidified incubator and animals were reinoculated in 1989 with the HIV-2 ROD isolate, after one passage in a macaque that exhibited half of the cell suspension was replaced by fresh culture medium on Days 3, 5, 7, 9, and 11. On Day 14, microplates an AIDS-like disease, as previously reported (Dormont et al., 1989 . Two years before SIV challenge, one were examined under an inverted microscope for syncytium formation, and the cell suspension was lysed with animal was transfused with 10 ml of whole blood from one HIV-2-infected monkey. 50 ml of 2.5% Nonidet-P40 detergent solution (Sigma). For the SIV antigen detection assay, 100 ml of the cell The pathogenic SIVmac251 cell-free virus stock used for intrarectal challenge was provided by Dr. A. M. Aubersuspension was used to coat ELISA microplates (Nunc, Roskilde, Denmark) for 1 night at 37Њ. Plates were then tin (Université Louis Pasteur, Strasbourg, France). This virus was grown on rhPBMCs without previous passage washed three times with 300 ml of PBS and saturated for 1 hr at 37Њ with 300 ml of PBS and 5% nonfat milk. Next, in normal or transformed human cells. According to Spouge (1992) , this virus stock contains 2 1 10 2 50% plates were washed five times with PBS containing 0.1% Tween 20 (Sigma). The antibody solution for SIV antigen intrarectal animal infectious dose (irAID 50 ) per milliliter (Le Grand and Dormont, 1993) and 4 1 10 4 intravenous detection was provided by a pool of inactivated sera from SIVmac251-infected macaques, diluted 10 03 in a solution AID 50 per milliliter . In 1994 all the HIV-2-seropositive animals and two naive controls were of PBS, 0.1% Tween 20, and 5% milk. Plates were incubated for 2 hr at 37Њ with this anti-SIV serum and then challenged by the rectal route with 10 irAID 50 of SIVmac251 virus stock. Before SIV inoculation, the animals washed five times as indicated above. Anti-SIV antibodies were detected by 1 hr of incubation with peroxidasewere subjected to 48 hr of hydric diet. labeled goat anti-monkey IgG (Organon Teknika, , respectively. The pol outer and inner uphout, Belgium) in a solution of PBS, 0.1% Tween 20, and 5% milk. Plates were then washed five times as indicated stream primer pairs designated SPEP and SPIP were 5-ATTCCACTTACCAGTTGAGAGG-3 (nucleotides 3988-above and once with PBS alone. Peroxidase activity was revealed by incubating the plates for 30 min in the dark 4009) and 5-ACAGTGGTGGACAGACTATTGG-3 (nucleotides 4021-4042), respectively. The pol outer and inner in a solution of 0.1% H 2 O 2 , 3 mg/ml orthophenilendiamine (Sigma) and 0.05 M citrate, pH 5.6. The reaction was downstream primer pairs designated SPEN and SPIN were 5-CAGGTGTCTACTATCTGTCTGG-3 (nucleotides stopped with 50 ml of 4 N H 2 SO 4 solution. The optical density (OD) of the plates was read at 490 nm (cutoff is 4602-4623) and 5-GCCTGCTCTCTGATTCTGTAGG-3 (nucleotides 4352-4373), respectively. the average OD of 12 uninfected control wells of the same culture microplate / 2.201 SD). Titers of cell-assoPolymerase chain reaction procedure. The first-round reaction mixture contained total genomic DNA (1 mg), the ciated virus load were determined using the Kärber method (1931) .
outer pair of primers (25 pmol each), dNTPs (100 mM each), 10 ml of Taq polymerase buffer (10 mM Tris-HCl, p27 antigenemia pH 8.3), 1.5 mM MgCl 2 , 50 mM KCl, 0.1% Triton X-100, and 0.5 units of Taq polymerase (Appligen, Illkirch, The p27 nucleocapsid protein was detected in undiFrance). Initial denaturation was performed at 94Њ for 4 luted plasma using the Coulter SIV core Ag assay (Retromin. The primers were annealed for 90 sec, at 60Њ for virology Coulter Corporation).
all outer primer pairs (HGEP/HGEN, HPEP/HPEN, SEEP/ SEEN and SPEP/SPEN), 63Њ for HIV-2-specific inner primPolymerase chain reaction ers (HGIP/HGIN), and 60Њ for SIV-specific inner primers. The templates were amplified at 72Њ for 35 cycles. For PBMCs isolated from macaques were lysed overnight with proteinase K in a PCR lysis buffer. DNA was obthe second round of amplification using the inner primer pairs, 1 ml of the first amplification mixture served as tained by the phenol-chloroform extraction method and 1 mg of total DNA was used as template for amplification.
template. To assess the validity of the results of each PCR assay, DNA from HIV-2-infected huPBMCs, DNA Two nested sets of oligonucleotide primers specific for the env and pol genes of SIVmac251 and two nested from SIV-infected rhPBMCs, and DNA from uninfected rhPBMCs were used as HIV-2 and SIV positive and negasets of oligonucleotide primers specific for the gag and pol genes of HIV-2 ROD were used. In these oligonucleotive controls and were included in each assay. Amplified products were resolved by 1% agarose gel electrophoretide sequences of the primer pairs listed below, there is no cross-reaction between the SIVmac251 and the HIV-2 sis and detected by ethidium bromide staining. The amplified DNA sequences were then blotted onto Hybond-ROD strains under the experimental conditions we used.
HIV-2-specific primers. The gag outer and inner up-N membrane for hybridization with 32 P-labeled probes. Oligonucleotidic probes specific for HIV-2 gag, HIV-2 pol, stream primer pairs designated HGEP and HGIP were 5-GAAGCAGCAGAATGAGATGT-3 (nucleotides 1173-SIV env, and SIV pol were 32 P-radiolabeled using the 5-end-labeling method and hybridized with the correspond-1192) and 5-TGACATAGCAGGGACAACAAGC-3 (nucleotides 1250-1271), respectively. The gag outer and inner ing PCR product blotted onto the nylon filter. downstream primer pairs designated HGEN and HGIN Detection of HIV-2-and SIV-specific antibodies were 5-TGTCATGGCTTACCACACTT-3 (nucleotides ELISA. Antibody responses were tested in plasma. 1785-1804) and 5-TAAATGCCTTTCTCTGCTGG-3 (nuAnti-HIV-2 serum reactivity was determined using an HIVcleotides 1694-1713), respectively. The pol outer and 2 antigen detection ELISA (ELAVIA II; Sanofi Diagnostics inner upstream primer pairs designated HPEP and HPIP Pasteur, France). Anti-SIV plasma reactivity was deterwere 5-CAGAGAGAGAGACCATACAAGG-3 (nucleomined using an SIV antigen detection ELISA based on tides 1986-2007) and 5-ACCAACAGAGGACTTGCTGCwhole lysate of SIVmac251-infected CEMX174 cells. The 3 (nucleotides 2063-2082), respectively. The pol outer ELISA titer corresponded to the reciprocal of the last and inner downstream primer pairs designated HPEN plasma dilution that resulted in significant positive optical and HPIN were 5-AGGATTAGTTGGAGGTGCTTCC-3 density (Le . (nucleotides 2524-2545) and 5-GTGTCGCCTGTCATTWestern blot analysis. Specificity against different SIV ATGGTGG-3 (nucleotides 2301-2322), respectively.
(or HIV-2) proteins was confirmed by Western blot (New-SIV-specific primers. The env outer and inner upstream LAV-Blot II; Sanofi-Diagnostics Pasteur). The anti-human primer pairs designated SEEP and SEIP were 5-GAGIgG in the kit was replaced by goat anti-monkey IgG AATACAGTCACAGAACAGG-3 (nucleotides 6814-6835) (Organon Teknika). and 5-CAACAATAACAACAGCAGCACC-3 (nucleotides Virus neutralization assay 6962-6983), respectively. The env outer and inner downstream primer pairs designated SEEN and SEIN were 5-In a 96-well flat-bottom culture microplate, serial dilutions (in quadruplicate) of serum to test were incubated CATTGATTGGTTGTGAGTGG-3 (nucleotides 7575-7594) 
a Macaque 37207 was transfused with 10 ml of blood from another macaque that had received one inoculation of HIV-2R0D33215 isolate in 1989. b Values are expressed in log 10 of the last positive dilution. Ab, antibodies. c Virus isolation from HIV-2-preinoculated macaques was positive at various time points until 10 months after the second HIV-2 inoculation. Virus was isolated using human PBMCs as target cells in cocultures with simian PBMCs obtained from HIV-2-infected monkeys.
d PCR was done 8 months after the second HIV-2 inoculation on peripheral blood mononuclear cells and on lymph node mononuclear cells(LNMC).
with 10-fold tissue culture 50% infectious doses (TCID 50 ) cules. Cells were then washed three times with 2 ml of PBS and fixed with 1% paraformaldehyde in PBS. Freof the virus stocks for 2 hr at 37Њ, in PBS supplemented with 10% complement-depleted sera collected from quency of each cell subset was evaluated using a FACS analyzer (Becton-Dickinson). Labeling of B cells with healthy and uninfected macaques. Controls were run as specified above in the absence of serum. The virus stock anti-CD20 monoclonal antibody (Becton-Dickinson), and of monocytes with anti-CD11b monoclonal antibody (Becused was provided by a cell-free supernatant of in vitroinfected monkey PBMCs. CEMX174 cells (2.5 1 10 4 ) were ton-Dickinson), was also performed in order to confer quality controls. added to each well. After 1 hr of infection at 37Њ, cell suspensions were washed three times in PBS and maintained in culture medium in a 5% CO 2 humidified incuba-RESULTS tor at 37Њ. On Days 3, 5, 7, 9, and 11 of culture, half of the cell suspension was replaced with fresh culture Status of monkeys before SIVmac251 challenge medium. On Days 7 and 14, 100 ml of the cell suspension
The results of macaque inoculation with HIV-2 ROD in each well was treated for 30 min at 4Њ with 20 ml of have already been published ; Nicol-2.5% Nonidet-P40 detergent solution and used to coat Jourdain et al., 1993) . Briefly, all six HIV-2 ROD-inoculated ELISA plates (Nunc). An ELISA was performed for the animals were persistently infected for several years, as detection of viral antigen production as previously deconfirmed by virologic and biologic analysis (Table 1) . On scribed by Makoschey et al. (1994) . The titer of the virus the day of SIVmac251 challenge, all six HIV-2-preinfected alone (TCID 50 V) and the titer of the virus with the different animals were negative for virus isolation on human serum dilutions (TCID 50 S) were calculated by the Kärber PBMCs, p27-Gag antigenemia, and DNA sequence demethod. Neutralization was considered to be efficient tection by PCR in PBMCs and lymph nodes. However, when the TCID 50 S:TCID 50 V ratio was 0.1 or less.
anti-HIV-2 antibodies were detected by ELISA in all animals with titers ranging from 10 2 to 10 3 ( Table 1 ). On that Circulating T lymphocyte subset determination day, only two macaques, 34433 and 33209, exhibited anti-SIV neutralizing antibodies with titers of 10 2 and 10 1.69 , Variations in absolute counts of T lymphocyte subsets were monitored during the investigation period by direct respectively. On the day of SIV challenge, immunoblot analysis immunofluorescence assay using either whole blood as described previously (Benveniste et al., 1996) or Ficollshowed that plasma samples from four of the six animals challenged, including those with anti-SIV neutralizing anisolated monkey PBMCs. Briefly, 5 1 10 5 freshly isolated or cryopreserved PBMCs were incubated for 30 min at tibodies, were reactive against the gp105-Env antigen.
Five of six macaques exhibited anti-p27-Gag antibodies. 4Њ with anti-Leu 3a-PE or anti-Leu 2a-FITC monoclonal antibodies (Becton-Dickinson, Mountain View, CA), rePlasma of monkey 37207 was reactive only with p27-Gag antigen. On the day of challenge, no reactivity was spectively specific for CD4 or CD8 cell surface mole-detected in the plasma of monkey 34771 against any Five of the six superinfected animals and both controls exhibited high cell-associated virus loads ranging from viral antigen by immunoblot analysis, despite its positive reactivity by ELISA, which is a more sensitive assay.
281 to 584 TCID 50 ; these loads peaked between the 2nd and 3rd weeks p.c. (Table 3) . Outcome of the SIVmac251 intrarectal challenge Viral antigenemia. Transient plasma p27-Gag antigenemia was detected in the control animals and in four of Clinical observations. Two monkeys (33219 and 34782) developed clinical and biological signs of immunosupthe six HIV-2-preinfected monkeys within the 2nd week after SIV challenge. In three of these four macaques, pressive disease: skin rash, weight loss, and wasting syndrome. Monkey 34782 died from disease by Week 14 p27-Gag antigenemia peaked within 2 or 3 weeks p.c. and thereafter dropped and became transiently negative after SIV challenge. Another superinfected animal (37207) died of disease unrelated to immunosuppresor weakly positive during the chronic infection period (data not shown). The fourth animal (34782) remained sion. Like the HIV-2-preinfected macaques, the two control animals inoculated with SIV also exhibited weight persistently p27-Gag-positive until death 14 weeks p.c. In contrast, no p27-Gag antigen was detected in the loss and wasting syndrome.
Circulating T lymphocyte subset determination. In plasma of preinfected animals 34433 and 37207 during the investigation period. In the naive controls, the antigen four of six HIV-2-preinfected macaques, circulating CD4-positive cell counts dropped significantly during level was two to five times higher than in preinfected animals. acute infection after the SIV challenge. Thereafter, during the chronic infection period, these counts dropped Viral DNA detection in PBMCs. The presence of SIVmac251 provirus in the circulating PBMCs of challenged progressively in the five superinfected animals. In monkey 34433 which had a low CD4/ count before the macaques was confirmed by qualitative nested PCR (data not shown). Five of the six superinfected animals challenge, no significant decrease was seen in circulating CD4-positive cell count. In the two controls, the and the naive controls were PCR positive for both env and pol SIV-specific primer pairs within 2 weeks p.c. No total number of circulating CD4/ cells also dropped significantly (Table 2) .
SIV-specific DNA was detected in the PBMCs of macaque 34433 over the 14 months of follow-up. This monAntibodies to viral antigens. Plasma samples were tested for antibody reactivity. The response to virus chalkey was then euthanized and no SIV or HIV-2 provirus was detected in its peripheral lymph nodes, spleen, or lenge of the HIV-2-preinfected macaques differed from the response of the naive controls as regards antibody PBMCs. HIV-2-specific primer pairs chosen in the gag and pol genes were also tested, in an attempt to evidence profiles. In HIV-2-preinfected animals, anti-SIV antibody titration by ELISA showed that five of the six macaques any resurgence of HIV-2 provirus in SIV-infected animals.
No HIV-2-specific DNA was detected in the PBMCs of developed an anamnestic response against viral antigens by the 2nd week after SIV inoculation (Fig. 1A) .
any of the superinfected macaques during the follow-up period. Hybridization of amplified DNA fragments with By contrast, in the controls, antibodies were only first detected by ELISA 4 weeks after SIV exposure, and there-32 P-labeled probes specific to either SIV or HIV-2 also showed that the DNA sequences detected in PBMCs after exhibited a gradual increase in titers for 3 months (Fig. 1B) . We failed to detect any enhancement in the from challenged animals were SIV-specific. plasma antibody response of HIV-2-preinfected monkey 34433 after SIV challenge. Western blot analysis showed DISCUSSION that antibodies directed against the gp140-Env precursor were not detectable on the day of SIV inoculation. In HIVFive of the six HIV-2-preinfected macaques included in our study belonged to a group of 9 macaques that 2-preinfected animals, these antibodies appeared within 4 weeks of challenge. In the naive control monkeys they were intravenously inoculated with HIV-2 ROD or HIV-2 EHO isolates in 1987 (Dormont et al., 1989) . Eight months appeared later (Fig. 2) . At various time points after SIV inoculation, the plasma from all seropositive animals exlater, 1 of the animals infected with HIV-2 ROD (33215), which exhibited evident clinical signs of simian AIDS, hibited strong reactivity to all SIV antigens, especially to p27-Gag and transmembrane gp36-Env.
was euthanized. Twenty months after the first inoculation of HIV-2, the virus isolated from the macaque 33215 Virus isolation from PBMCs. SIV was recovered easily every week during the 1st month postchallenge (p.c.) in PBMCs was used to reinoculate the surviving animals. This second intravenous inoculation led to persistent infive of the six challenged animals and in the two controls (Table 3 ). In contrast, no virus could be recovered from fection and a decrease of CD4/ cell counts in all macaques. Two animals subsequently died after developing monkey 34433, the one which exhibited the highest neutralizing antibody titer on the day of challenge. The virus AIDS-like symptoms 6 months and 5 years after reinoculation (Nicol-Jourdain et al., 1993). Four years after reinocwas also reisolated from the four surviving superinfected animals at several time points throughout the 14-month ulation, whole blood from 1 of these animals was transfused to a naive monkey. Transmission of HIV-2 to this investigation period. monkey was confirmed by successful virus isolation from only developed transient SIV viremia, and no evidence of immunodeficiency was detected for more than 5 years its PBMCs and by seroconversion. Three to five years after HIV-2 reinoculation, the surviving animals remained after challenge, at least in three of the four HIV-2-preinfected monkeys. Conversely, naive controls developed healthy and were negative for p27-Gag antigenemia, HIV-2 provirus detection in PBMCs and lymph node cells, persistent SIV viremia and died within 8 to 38 weeks of SIV inoculation. The above authors therefore concluded and HIV-2 provirus isolation from PBMCs. However, all these monkeys were still seropositive, exhibiting antithat HIV-2 infection had ''vaccinated'' macaques against SIV intravenous infection. HIV-2 ELISA titers ranging from 10 2 to 10 3 . Therefore, taking all these results together, we may conclude that
We designed a similar experiment, in order to assess, in macaques, the vaccine effect of HIV-2 infection against HIV-2 inoculation led to chronic infection in these rhesus monkeys. Nevertheless, this virus strain may be considan atraumatic intrarectal challenge with a pathogenic SIVmac251 biological isolate. Since in humans, natural HIV ered weakly pathogenic, because during an observation period exceeding 6 years, AIDS was only observed in 3 of infection mainly occurs by sexual transmission, a vaccine strategy should induce not only a good anti-viral systemic the 10 inoculated monkeys. These results are concordant with those published by others who observed few or no response but also effective mucosal immunity. In our experiment, intrarectal exposure to SIVmac251 established evident clinical signs of AIDS in cynomolgus or rhesus macaques chronically infected with HIV-2 SBL isolate chronic superinfection in five of the six HIV-2-preinfected rhesus macaques, as confirmed: (1) by the induction of an (Putkonen et al., 1990) or Ben isolate (Petry et al., 1995; Stahl-Hennig et al., 1990) .
anamnestic antibody response, (2) by SIV isolation in the coculture of PBMCs, and (3) by SIV provirus detection in Putkonen et al. recently reported that HIV-2-preinfected cynomolgus macaques could be intravenously suPBMCs. No significant differences were observed between the cell-associated virus loads of HIV-2-preinfected animals perinfected with a pathogenic strain of SIV (Putkonen et al., 1995) . However, in their experiments, the animals and controls. Using the SIV-specific and HIV-2-specific Four of our five superinfected monkeys were positive for p27-Gag antigenemia. This antigenemia peaked by the 2nd week after SIV challenge and dropped to weak values during the chronic infection. p27-Gag antigenemia was two to five times higher in controls than in HIV-2-preinfected macaques. On the 2nd week after challenge, at the time of the peak of p27-Gag antigenemia, antibodies induced by the anamnestic response were at high titers. These antibodies could react with core antigen and therefore partially neutralized the in vitro assay, making it difficult to interpret the differences between the control and vaccinated groups.
Finally, after challenge with SIV, five of six HIV-2-preinfected macaques exhibited a significant decrease in the circulating CD4/ cell count. Two of these monkeys exhibited clinical symptoms related to simian AIDS and one of these two animals died. In contrast to the results reported by Putkonen et al., our findings therefore suggest that our HIV-2-preinfected animals which were not resistant to SIV rectal challenge were also not protected from disease progression.
Only one of the animals we challenged (34433) resisted superinfection and remained negative for all SIV infection criteria for 14 months p.c. Interestingly, on the day of SIV challenge, this macaque exhibited the highest anti-HIV-2 and anti-SIV ELISA titers, as well as the highest anti-SIVmac251 serum neutralizing activity. Western blot data showed that plasma from this same macaque exhibited high reactivity against the gp105-Env, p27-Gag, and p17-Gag antigens. After SIV challenge, this animal did not seroconvert to new viral structural proteins, and its antibody titer, as evaluated by ELISA, did not rise.
Whether antibodies contribute to protection against lentiviral infection or prevention from disease progression is still controversial. Whereas in the chimpanzee model of human HIV-1 infection, several reports have strongly suggested that antibodies, most of them directed against the V3 loop of gp120, may contribute to FIG. 1. SIV-specific antibody response by (A) HIV-2 ROD preinfected sterilizing immunity (Berman et al., 1990; Bruck et al., and (B) naive control rhesus macaques after intrarectal challenge with Girard et al., 1991) , no such contribution by SIVmac251. Plasma samples obtained at various time points postchalhumoral immunity to protection could be concluded from lenge were tested in duplicate at dilutions ranging from 10 01 to 10 07 . ELISA titers are expressed as log10 of the reciprocal of the last plasma the SIV or HIV-2 macaque models.
dilution that resulted in a significant positive optical density.
Varied vaccine strategies have been implemented in the SIV-macaque model of human lentiviral infection. From most of these experiments, including those involving a primer pairs, we also demonstrated the presence of SIV large number of animals (Dormont et al., 1995) , only vacprovirus at several time points in the PBMCs of the five cines using ''live attenuated'' SIV clones, like those deleted superinfected animals, whereas no HIV-2 provirus was dein the nef region of the genome, seem to confer at least tected over an investigation period of 14 months after SIV partial protection against SIV infection, as confirmed by challenge. Therefore, SIV mucosal superinfection did not the reduction in the virus load during acute infection and seem to reactivate HIV-2 replication in vivo, contrary to significant delaying of the development of simian AIDS what others previously reported (Petry et al., 1995) . We may (Almond et al., 1995; Daniel et al., 1992; Kieny et al., 1993) . therefore conclude that anti-viral immunity induced by HIVIn none of these experiments could a clear correlation 2 infection does not prevent a high virus load during acute be established between anti-viral-induced immunity and SIV viremia, as demonstrated by other studies using live protection by neutralizing antibodies or antigen-specific attenuated vaccines (Almond et al., 1995; Daniel et al., 1992) .
cytotoxic T cells (Hulskotte et al., 1995) .
FIG. 2.
Immunoblot analysis of antibodies to SIVmac251 in controls and HIV-2-preinfected macaques. GP, glycoprotein; P, protein; D, day; PC, positive control; NC, negative control.
All these assays were designed to assess protection tracks may facilitate virus excretion and therefore diminish SIV infectivity. Second, as reported for Sendai virus against experimental intravenous inoculation of SIV. However, the results of our experiments suggest that (Mazanec et al., 1992) , these complexes may block the passage of the virus from the apical to the basal pole of antibodies may interfere with virus mucosal exposure, because the only animal protected from SIV rectal chalthe epithelial cells, and therefore prevent its contact with the sensitive and competent virus-replicating mononulenge was the one exhibiting the highest anti-SIV humoral activity. As demonstrated for many mucosal pathoclear cells of the lamina propria. Third, these antibodies may mediate neutralizing activities, and therefore prevent gens, antibodies to lentiviral particles may constitute the first immune barrier, inhibiting virus transmission by difthe infection of intraepithelial T cells or mucosal macrophages. We did not in fact investigate the level of the ferent mechanisms. First, the immune complexes formed by the virus and the antibodies in the lumen of genital antibody response at the mucosal surface in the monkey 
